Rhythm Pharmaceuticals, Inc. - Common Stock (RYTM)

In a move that signals a significant consolidation within the rare endocrine disease market, Neurocrine Biosciences (NASDAQ: NBIX) announced on April 6, 2026, that it has entered into a definitive agreement to acquire Celeno Therapeutics (NASDAQ: SLNO). The all-cash transaction, valued at approximately $2.9 billion, underscores a strategic push

The following feature explores the trajectory of Soleno Therapeutics as of April 7, 2026. Introduction On the morning of April 7, 2026, the biotechnology sector is processing one of the most significant mid-cap success stories of the decade. Soleno Therapeutics (NASDAQ: SLNO) has transitioned from a struggling diagnostics firm to a commercial powerhouse, culminating in [...]

Shares of Soleno Therapeutics (NASDAQ: SLNO) surged more than 32% in early trading on Monday, April 6, 2026, following the blockbuster announcement that Neurocrine Biosciences (NASDAQ: NBIX) has entered into a definitive agreement to acquire the company. The all-cash transaction, valued at approximately $2.9 billion, represents a significant premium

This little-known biotech company has a different strategy than the established weight-loss drug market leaders. But is it likely to be successful?

Immunome develops antibody therapeutics for cancer and infectious diseases, reporting a market cap above $2 billion in the latest filing.

Liquidia develops inhaled and injectable therapies for pulmonary arterial hypertension, targeting unmet needs in the U.S. biopharma market.

Rhythm Pharma (RYTM) Earnings Call Transcript

Praxis Precision Medicines targets neurological and psychiatric disorders with a pipeline of precision therapies for CNS conditions.

Celcuity develops targeted cancer therapies and diagnostic platforms, with a focus on advancing precision medicine in oncology.

Apogee Therapeutics develops biologic therapies targeting dermatology and respiratory conditions, with lead candidates in clinical trials.

Arcellx develops next-generation cell therapies targeting multiple myeloma and other hematologic cancers in the biotechnology sector.

These stocks all have catalysts on the way that could provide great news for investors.

This biotech stock is flying under the radar for many investors, but Wall Street loves it.

As the curtain closes on 2025, the financial landscape presents a tale of two markets. While the S&P 500 (NYSEARCA: SPY) hovers near the historic 7,000-point milestone, fueled by a 19% year-to-date rally and a resilient "soft landing" for the U.S. economy, a stark divergence has emerged

As the final trading days of 2025 wind down, Rhythm Pharmaceuticals (Nasdaq: RYTM) finds itself at a critical crossroads. After a meteoric rise that saw the stock gain over 100% through the first three quarters of the year, the rare-disease specialist has encountered a late-year slump, retreating from its 52-week

The company was studying the therapy in Prader-Willi Syndrome, a rare genetic disorder requiring lifelong management.

Let's have a look at the gap up and gap down stocks in today's session.

Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session.

The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

Rythm Pharmaceuticals' (RYTM) Chief Technical Officer Sells 9,748 Shares for $1.1 Million

Rhythm Pharmaceuticals posts mixed Q3 2025 results, missing revenue estimates. Despite the loss, the company highlights strong drug growth and key regulatory milestones for its obesity treatments.